Clinical Trial

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Name: A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors — clinical trial record (NCT07612176)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Trial Details

NCT Number	NCT07612176
Lead Sponsor	NEOK Bio, Inc.
Conditions	Locally Advanced (Unresectable) or Metastatic Solid Tumors
Enrollment	155 participants
Start Date	2026-04-21
Primary Completion	2029-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-28